Clinical Trials
3 trialsNCT05627245 2026-05-13
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT00354185 2013-05-16
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00348985 2013-05-03
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Phase 1 Completed